The In Vitro Diagnostics Quality Control Market is primarily driven by the rising number of accredited clinical laboratories, increasing demand for third-party quality controls, and rising prevalence of chronic and infectious diseases.

According to research report the global In Vitro Diagnostics Quality Control Market size is projected to reach $1,158 million by 2025 from $961 million in 2020, at a CAGR of 3.8% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198032582

By identifying over 30,000+ growth opportunities through our unique market research methodology, markets and markets help grow your business, drive market performance and assess potential business disruptors.

The market is segmented by Source (Plasma, Whole Blood, Urine), Technology (Immunoassay, Hematology, Microbiology, Molecular Diagnostics), Manufacturer (Third-party, OEM), End Users (Hospitals, Lab) - Global Forecast to 2026

• On the basis of type, the quality control products market is segmented into serum/plasma-based controls, whole blood-based controls, urine-based controls, and other controls (controls manufactured from spinal fluid, lipoprotein extracts, and immunoproteins). The serum/plasma-based controls segment is expected to account for the largest market share in 2019.
  
  
• Based on applications, the IVD quality control market is segmented into clinical chemistry, immunochemistry, hematology, coagulation & hemostasis, microbiology, molecular diagnostics, and other applications (ESR, urine chemistry, immunology, cardiac assessment, and blood morphology). The molecular diagnostics segment is expected to grow at the highest CAGR during the forecast period.

• The immunochemistry segment accounted for the largest share of the IVD quality control market in 2020. Based on technology, the IVD quality control market is broadly segmented into clinical chemistry, immunochemistry, hematology, coagulation & hemostasis, microbiology, molecular diagnostics, and other technologies. The large share of this segment can be attributed to the increasing use of multi-analyte controls to perform immunoassay tests in laboratories. The use of immunoassay tests in clinical laboratories has also increased due to the high sensitivity of these tests over conventional methods.

The North America is expected to account for the largest share of the In Vitro Diagnostics Quality Control Market in 2020, followed by Europe. The large share of the North America can be attributed to the highly developed healthcare system in the US and Canada, and the presence of a large number of leading IVD quality control vendors & national clinical laboratories & hospitals in this region.

Some of the key players in the In Vitro Diagnostics Quality Control Market include Bio-Rad Laboratories, Inc. (US), Randox Laboratories Ltd. (UK), Thermo Fisher Scientific, Inc. (US), LGC Limited (UK), and Abbott Laboratories (US).

Request For Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=198032582

Key players are focusing on increasing their presence in this growing market through both organic as well as inorganic growth strategies, such as product launches, agreements, partnerships, collaborations, and expansions. Due to the intense competition in this market, various market players are increasingly focusing on expanding their geographic presence in high-growth emerging markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]